Filtered By:
Condition: Heart Attack
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 1021 results found since Jan 2013.
Potential role for pentoxifylline as an anti-inflammatory drug for patients with acute coronary syndrome
Exp Ther Med. 2022 Jun;23(6):378. doi: 10.3892/etm.2022.11305. Epub 2022 Apr 8.ABSTRACTThe link between inflammation and acute coronary syndrome (ACS) remains to be sufficiently elucidated. It has been previously suggested that there is an inflammatory process associated with ACS. Pentoxifylline, a methylxanthine derivate, is known to delay the progression of atherosclerosis and reduce the risk of vascular events, especially by modulating the systemic inflammatory response. The present study is a single-blind, randomized, prospective study of pentoxifylline 400 mg three times a day (TID) added to standard therapy vs. stand...
Source: Experimental and Therapeutic Medicine - May 2, 2022 Category: General Medicine Authors: Daniel Miron Brie Cristian Mornos Diduta Alina Brie Constantin Tudor Luca Lucian Petrescu Madalina Boruga Source Type: research
Statin side effects: Risk of drug-induced eczema may be ‘significant' among users - study
STATINS have significantly softened the burden of heart disease, slashing the risk of heart attack and stroke for thousands. But the drugs' associations with muscle-related complications continue to be problematic. According to some findings, the pill may also carry a risk of eczema.
Source: Daily Express - Health - April 26, 2022 Category: Consumer Health News Source Type: news
Cardiovascular Risk and Treatment Outcomes in Severe Hypercholesterolemia: A Nationwide Cohort Study
Conclusions Using large Korean cohort data, our study proved incrementally elevated cardiovascular risk and clinical benefit associated with LDL-C<100 mg/dL in individuals with severe hypercholesterolemia. These results support aggressive lipid lowering and provide evidence for the LDL-C target in this population.PMID:35470675 | DOI:10.1161/JAHA.121.024379
Source: Atherosclerosis - April 26, 2022 Category: Cardiology Authors: Chan Joo Lee Sanghyun Park Kyungdo Han Sang-Hak Lee Source Type: research
PCSK9 and Cardiovascular Disease in Individuals with Moderately Decreased Kidney Function
Conclusions: Our findings reveal no relation of PCSK9 with baseline eGFR and albuminuria, but a significant association between higher PCSK9 concentrations and risk of cardiovascular disease independent of traditional risk factors including LDL-cholesterol levels.PMID:35387881 | DOI:10.2215/CJN.01230122
Source: Clinical Journal of the American Society of Nephrology : CJASN - April 7, 2022 Category: Urology & Nephrology Authors: Azin Kheirkhah Claudia Lamina Barbara Kollerits Johanna Schachtl-Riess Ulla Schultheiss Lukas Forer Peggy Sekula Fruzsina Kotsis Kai-Uwe Eckardt Florian Kronenberg Source Type: research
RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus
AbstractDiabetic dyslipidemia is characterised by low HDL-C and high triglyceride levels. Unlike the Caucasian population, though LDL-C levels are not very high, there is a preponderance of more atherogenic small, dense LDL particles among Indians. Furthermore, apo B levels are elevated. This, unique ‘atherogenic dyslipidemia’, is frequently encountered in South Asians with diabetes. People with type 2 diabetes are considered to be at high risk for vascular events. Hence, irrespective of other risk factors such as age, male gender, hypertension, family history, smoking, obesity, and polycyst ic ovary syndrome in women,...
Source: International Journal of Diabetes in Developing Countries - April 7, 2022 Category: Endocrinology Source Type: research
'Dangerous': Stopping statins can 'significantly' increase risk of a heart attack - doctor
STATINS can slash your risk of serious cardiovascular problems by lowering high cholesterol levels. To reap the benefits and mitigate the risks, you usually have to take statins for life. According to Doctor Afzal Sohaib, consultant cardiologist at The Wellington Hospital, part of HCA Healthcare UK, coming off statins "completely" can hike your risk of a heart attack or stroke.
Source: Daily Express - Health - April 3, 2022 Category: Consumer Health News Source Type: news
Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Comparing pharmacotherapy in MINOCA versus medically managed obstructive acute coronary syndrome
This study uniquely compares the management and outcomes of MINOCA patients with a medically managed obstructive ACS (M-ACS) population. We retrospectively analysed registry data for consecutive patients admitted to the Gold Coast University Hospital with ACS requiring coronary angiography and identified patients with MINOCA and M-ACS. Baseline characteristics, pharmacological therapy and in-hospital outcomes were compared. In hospital outcomes were composite NACE, heart failure, stroke and major bleeding. Multivariate regression analysis was also performed to identify independent predictors of MINOCA. Multivariate regress...
Source: Heart and Vessels - March 23, 2022 Category: Cardiology Source Type: research
Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment
This systematic review and meta-analysis examines the association between absolute reductions in low-density lipoprotein cholesterol levels with treatment with statin therapy and all-cause mortality, myocardial infarction, and stroke.
Source: JAMA Internal Medicine - March 14, 2022 Category: Internal Medicine Source Type: research
Myocardial Infarction, Stroke, and All-Cause Mortality According to Low-Density Lipoprotein Cholesterol Level in the Elderly, a Nationwide Study
CONCLUSION: Among the elderly, lower LDL-C was associated with decreased risks of MI and stroke. Lower LDL-C achieved by statins in the elderly was associated with a decreased risk of all-cause death during follow-up, suggesting that LDL-C paradox for the premature death risk in the elderly should not be applied to statin users. Intensive statin therapy should not be hesitated for older adults with cardiovascular risk factors including diabetes.PMID:35255552 | DOI:10.4093/dmj.2021.0225
Source: Diabetes and Metabolism Journal - March 7, 2022 Category: Endocrinology Authors: You-Bin Lee Minji Koo Eunjin Noh Soon Young Hwang Jung A Kim Eun Roh So-Hyeon Hong Kyung Mook Choi Sei Hyun Baik Geum Joon Cho Hye Jin Yoo Source Type: research
